Treatment of healthy rats and mice with a single intravenous injection of recombinant human tumor necrosis factor-alpha (rHuTNF-a) caused a dose-dependent gastrointestinal inflammation. Within 30 min gastric emptying was blocked and tissue edema occurred in the small and large intestine. In the cecum hemorrhage occurred after 4 h at doses 2 250 ag/kg. The cecum exhibited an acute inflammatory response following rHuTNF-a treatment similar to that seen in tumor necrosis at the same dose. The vascular endothelium became swollen, increased numbers of neutrophils and other leukocytes attached to and penetrated the endothelium, and finally hemorrhage occurred. Treatment of rats with daily injections of rHuTNF-a (250 tig/kg per d) for 3 wk failed to produce cachexia. Within 2448 h rats became resistant to the hemorrhagic effect of rHuTNF-a, however, the cytokine still caused a transitory block of gastric emptying after 10 d of treatment. Treatment at 5-or 10-d intervals produced results similar to the initial injection. These results suggest that maximum hemorrhagic response will occur when rHuTNF-a is administered at intervals of 5-10 d rather than daily.
Introduction
In 1975 Carswell et al. discovered a factor in the serum of bacteria primed, endotoxin-treated animals that could induce hemorrhagic necrosis of tumors in recipient animals (1) . They called this active principle tumor necrosis factor (TNF).' Since then, two TNFs have been isolated and characterized; TNF-a, a product primarily of macrophages and to a lesser degree natural killer cells, natural cytotoxic cells, and interleukin 3 dependent bone marrow-derived mast cells, and TNF-f3, a product of B-lymphoblastoid cells (2) . The TNFs are now known to be members of a larger group of inducible hormonelike proteins called cytokines that help regulate the host metabolic and immunological response to infection.
The mechanism of tumor necrosis by TNF is poorly understood although evidence suggests that TNF induces a classical acute inflammatory response in the tumor that leads to 1 . Abbreviations used in this paper: GI, gastrointestinal; Meth A, methylcholanthrene A; rHuTNF-a, #; recombinant human tumor necrosis factor-alpha, beta; TNF, tumor necrosis factor. disruption of the tumor's blood supply (3, 4) . Palladino et al. have shown that subcutaneously implanted methylcholanthrene (Meth A) tumors, which are well vascularized, are necrosed by TNF-a, while intraperitoneal tumors of the same cells, which are poorly vascularized, are not affected by TNF-a (4). They further showed that, in vitro, the Meth A tumor cells were relatively insensitive to TNF (4) . Thus, the primary tumor lesion induced by TNF-a in the Meth A model appears to be vascular. Others have shown that TNF-a stimulates neutrophil adherence to endothelial cells in vitro by increasing the affinity of both cells for each other (5, 6) and that TNF-a activates the cytotoxic and phagocytic activities of neutrophils (7) , which, if directed towards endothelial cells, could destroy them (8) . Both of these events are components of the inflammatory response (9) and may contribute to the passage of phagocytic cells and other cells through endothelium. It is still unclear, however, how much of TNFs antitumor effects are due simply to effects on the vasculature of the tumor. In vitro TNF has direct cytotoxic activity against a variety of tumor cell lines (10) and can stimulate the tumoricidal activity of macrophages (1 1). Thus TNF-induced tumor regression in the absence of hemorrhagic necrosis should be possible, particularly with TNF-sensitive intraperitoneal tumors (12) .
Suppression of food intake and anorexia commonly occur during infection. In experiments where anorexia in mice acutely infected with Listeria monocytogenes was overriden by force feeding, mortality was increased and survival time shortened in force fed animals (13) . Murray and Murray have summarized the literature on the inhibition of infection by famine and its activation by refeeding; they suggest that loss of appetite in infected animals plays a vital role in host defense as part of a purposeful redistribution of nutrients that contributes to "6nutritional immunity" during infection (14, 15) . There is now evidence that suppression of food intake may be caused by endogenous cytokines. In human clinical trials with alpha and gamma interferon, anorexia, nausea, and vomiting were frequent side effects (16, 17) . In studies with fasted rats, both Escherichia coli endotoxin and interleukin 1 (another cytokine) have been shown to suppress food intake (18) . In addition, Cerami and co-workers have shown that a solution of macrophage secretory products, which may contain interleukin 1 (19) as well as TNF-a, induced suppression of food intake in mice (20) . Thus interferons, interleukins, and TNFs have all been implicated as causative agents in suppression of food intake during infection.
In this study we have examined the effects of rHuTNF-a on gastrointestinal (GI) structure and function in rodents. The results suggest that rHuTNF-a suppresses food intake by inhibiting gastric emptying as a prelude to an inflammatory response in intestinal tissue. At high rHuTNF concentrations, hemorrhage occurs in rat cecum in a manner similar to that Methods Cytokines. Recombinant human tumor necrosis factor-alpha (rHuTNF-a), -beta (rHuTNF-fl), recombinant murine tumor necrosis factor-alpha (rMuTNF-a), and recombinant murine interferon gamma (rMuIFN-'y) were produced in Escherichia coli as described (21) (22) (23) (24) Time course of antibody formation in rats. The purpose of these experiments was to determine the time course of antibody production in response to daily injections of rHuTNF-a (0.25 mg/kg). The experiment was identical to the metabolic cage study except that consumption and excretions were not measured and only the first injection was intravenous with remaining injections intramuscular. 21 animals were used and groups of three were killed on days 0, 3, 5, 7, 9, 1 1, and 21 after receiving 0, 2, 4, 6, 8, 10, and 20 injections of rHuTNF-a, respectively. Animals were anesthetized 24 h after their last injection and their blood was drawn from the ventral aorta and stored at -700C until analyzed for antibodies to rHuTNF-a. Antibody titers to rHuTNF-a were determined by a radioimmune precipitation assay. rHuTNF-a was labeled with '25I by the Iodogen method as described by Aggarwal et al. (25) to a specific activity of 30-60 MCi/gg. Dilutions of test sera were incubated with 5.35-10.7 nCi (20,000 cpm)of 1251I-rHuTNF-a for 12-16 h. Immunoglobins were then precipitated by a specific second antibody, goat anti-rat IgG (Antibodies, Inc., Davis, CA), and the radioactivity in the pellets was counted. The titer was defind as the serum dilution that precipitates twice the number of counts precipitated by preimmune serum.
Neutralizing anti-rHuTNF-a antibody activity was estimated by incubating 400 U (-16 ng) of rHuTNF-a (in 100 jd PBS plus 1% bovine serum albumin) with known volumes of rat serum for 12-16 h at 4VC and then assaying for rHuTNF-a activity in the L-M cytotoxicity bioassay for human tumor necrosis factor (26 rMuTNF-a (data not shown). Fig. 2 also shows the average fecal outputs ofrats at different doses ofcytokine. These values were calculated from the total weight of feces collected from the group cages. The results show that rHuTNF-a caused an increase in fecal output that roughly paralleled the increase in weight of stomach contents.
To determine whether the increase in weight of stomach contents was caused by inhibition of gastric emptying or an increase in feeding, experiments were conducted to separately test each possibility. In the first, nonabsorbable 51Cr was instilled into the stomachs of mice at 30, 60, 90, and 120 min after they had received a bolus dose of rHuTNF-a (0.25 mg/kg i.v.). Mice were euthanized 30 min after delivery of 5"Cr and the location of the radioactivity in different regions of the GI tract determined. Fig. 3 shows results for control and rHuTNF-a treated animals. In control animals, almost all (> 90%) of the total administered 51Cr had moved into the small intestine after 30 min. In cytokine-treated animals, however, the nonabsorbable marker was retained primarily in the stomach. Thus, intravenous rHuTNF-a acts rapidly to block gastric emptying.
To determine if rHuTNF-a also induced feeding, food intake was measured during a 3.5 h period following a single bolus injection of rHuTNF-a (0.25 mg/kg i.v.) or PBS. Control animals ate a negligible quantity of food; 0.05±0.05 g/rat (n = 3). Some cytokine-treated animals also ate nothing, but others nibbled occasionally giving an average value for six animals of 0.65±0.62 g/rat. Unlike control animals who usually went back to sleep after their injection, cytokinetreated animals stayed awake and exhibited a characteristic hunched posture with their fur erect. Eating, when it did occur, was perfunctory and limited, and ceased entirely by 3.5 h. The increased weight of stomach contents in treated animals as compared to controls can therefore be explained by a marked decrease in gastric emptying and a slight increase in food consumption. Histology after single injection. At 3.5 h after a single dose of rHuTNF-a (0.25 mg/kg), both rats and mice exhibited similar histological changes in their small and large intestines compatible with mild enteritis. There was a mild accumulation of mononuclear and fewer neutrophilic inflammatory cells in the lamina propria of villi and intestinal glands. Along with the cell accumulation in the lamina propria there were a few pyknotic and fragmented nuclei and variably severe edema and lymphangiectasia. Another consistent and distinct change affecting those rodents injected with rHuTNF-a involved the vasculature. This change consisted of increased height (prominence) of the endothelium of small vessels, increased adherence of mononuclear and neutrophilic cells to the endothelial surface, and increased numbers of these same cells within vessel lumina.
Mice were also injected with a single very high dose of rHuTNF-a (16.5 mg/kg) and were examined 3.5 h postinjection. Stomach dilation was much less prominent than in groups treated with lower doses (Fig. 2) . Treated mice had variable degrees of necrosis and inflammation of intestinal mucosa. The necrotic change affected only crypt epithelial cells and was characterized by nuclear pyknosis, karyolysis and, rarely, sloughing of individual cells. There was no ulceration. The small intestine was more severely involved with only minimal involvement of the stomach and large intestine. Inflammatory changes involved the lamina propria ofthe mucosa and were characterized by accumulation of mononuclear and fewer neutrophilic inflammatory cells and the presence of scattered necrotic cells. These changes resulted in thickening and hypercellularity of intestinal villi lamina propria. Hemorrhagic foci were very rare. Vascular changes were identical to those seen at the lower dose.
Following a single injection of 0.25 mg/kg i.v. rHuTNF-a no hemorrhage was observed for -4 h; however, between 4 and 6 h postinjection, cecal hemorrhage was prominent in all rats treated. Hemorrhage was also noted in a section of uterus that was sectioned from one animal. The small intestine and stomach were rarely hemorrhagic. Fig. 4 (Fig. 4 D) were characterized by flattened endothelial cells (arrows) with few, if any, marginated neutrophils and other leukocytes. After 4 h (Fig. 4 E) considerable margination of leukocytes (arrows) to hypertrophied endothelium had occurred. By 24 h the migration and hypertrophy were severe. Various stages of leukocyte margination and endothelial cell hypertrophy are shown in Fig. 4 F plus the presence of leukocytes within the vascular wall and marked perivascular edema (asterisks).
Blood chemistry and cell numbers. The profound GI changes caused by rHuTNF-a (0.25 ,ug/kg) were accompanied by relatively few significant changes in blood components. Of 32 standard blood indices measured, only 3 exhibited significant differences between control and treated animals. Neutrophil numbers were increased, lymphocyte numbers decreased and triglyceride levels were elevated by rHuTNF-a treatment (Table I) . At 1.5 h there was no significant difference in cell numbers between control and treated animals, however, at 3 and 4.5 h postinjection, neutrophil numbers increased roughly fourfold and lymphocyte numbers decreased two-to fourfold. Triglyceride concentrations were measured only in females and showed a three-to sixfold increase over controls after rHuTNF-a treatment. Blood urea nitrogen (BUN) and creatine concentrations were slightly increased in treated animals (data not shown).
Chronic multiple injection studies. The effects of daily injections of rHuTNF-a (0.25 mg/kg) on GI function were studied by placing rats in individual metabolic cages and monitoring their daily food and water consumption, and feces and urine production. A total of nine animals were studied in the first experiment (three PBS treated and six-rHuTNF-a treated). Fig. 5 shows the results of a 24-d study. After 3 d, during which the animals became accustomed to their cages, the first intravenous injections were made. This led to a marked drop in the consumption of food and water by the rHuTNF-a treated animals as compared with the control animals in the first 24 h. Bloody stools were seen in four of the six rHuTNF-a animals. After the initial intravenous injection, intramuscular injections of the original dose were given on the next 4 d. During this period, food and water consumption rebounded and the second intravenous injection given on day 5 produced no obvious effect nor did any of the subsequent injections over the next 2 wk. The animals rapidly developed tolerance to the inflammatory effects of rHuTNF-a on the GI tract. At the end of the experiment, control animals gained an average of 18±9 g and treated animals 29±10 g. Blood chemistries were identical in both groups and no gross differences between groups were seen except in spleen weights, which averaged 510±50 mg in controls and 930±150 mg in the cytokine-treated rodents.
In a second experiment, only food intake and body weights were measured. In this 1 7-d experiment, animals were injected only intravenously (with 0.25 mg/kg rHuTNF-a) at either 5-or 10-d intervals. Fig. 6 shows the results of these dosage regimens on food intake. Injections every 5 d caused a marked decrease in food intake with the initial injection and a less dramatic decrease following two subsequent injections (Fig. 6  A) . Injections 10 d apart caused obvious decreases in food intake with both injections (Fig. 6 B) . The average response to the second injection appeared, again, to be less than the first. Animals showed transitory weight losses on days following injections but gained weight overall. These results suggest that a single injection of rHuTNF-a induces a partial tolerance to the GI response of subsequent injections that persists for at least 5 to IO d.
In another rat experiment, the effects of daily injections of rHuTNF-a on daily body weights and GI function and morphology after 10 d of treatment were studied. Fig. 7 compares the effects of two different doses of rHuTNF on body weight with the body weights of animals injected with PBS. Each point represents the mean of 6-10 animals. The higher dose of rHuTNF-a caused a marked loss of weight in the first 3 d of the experiment but complete recovery of weight loss occurred by day 10. Animals treated with the lower dose weighed the same as PBS-treated animals. In the high-dose group bloody stools were produced by all animals after the initial injection (two animals died). Some animals from this group were examined histologically 24 h after their final intramuscular injection.
On day 11, five control animals and six treated animals (three from each dose) were given an additional intravenous (6) 2,000±2,032 (6) 6,359±1,598 (6) 3,971±2,490 (5) Triglycerides (mg/dl)
43±13 (4) 258±130 (4) * 1 SD (n = number of animals).
trophils. Varying numbers of mixtures of these cells occurred throughout the submucosa and lamina propria (Fig. 8) of the cecum and occasionally other portions ofthe intestine. Inflammatory cell accumulations were several times more severe in rats receiving 0.25 mg/kg rHuTNF-a compared with those receiving 0.025 mg/kg. There was slight to moderate submucosal edema and lymphatic dilitation in several sites associated with both dose levels. Margination of neutrophils to vascular endotheliumn was not prominent. Several foci, present in cecum of high-dose rats, were composed of mixed inflammatory cells and granulation tissue that replaced mucosa and extended into the submucosa.'These foci resembled healing ulcers (Fig, 8 D) . Time course ofantibodyformation. Anti-rHuTNF-a antibodies began to appear by day 10 in rats injected intravenously on day 1 and all subsequent days intramuscularly (0.25 mg/kg per d rHuTNF-a) (Table II) . This experiment differed only slightly from the first metabolic cage study in which the dose Was administered i.v. on days 0, 5, and 12 and i.m. on all other days. From these results we conclude that the tolerance developed to rHuTNF-a by day 5 was not due to antibody formation.
Discussion
TNF had two major effects on the gastrointestinal tract of rats.
It cleared the small and large intestine of nutrients by inhibiting gastric emptying and accelerating movement of intestinal contents out of the animal, and it induced the flow of fluid (edema) and leukocytes into the GI tissue. ( 13) .
The hemorrhage that is caused in implanted tumors by endotoxin or TNF is similar to the hemorrhage seen in the rat cecum at similar TNF doses (4, 31 Since the rat cecum contains a large microbial community, and is at constant risk ofmicrobial invasion, a high responsiveness to TNF may insure a robust inflammatory response should infection occur.
2. Such doses are more than 50 times the current estimates for the maximally tolerated single dose in man and far above those recommended for phase II studies in man (27) . However, TNFs exhibit some species specificity and the LD50 of human TNF in rodents appears to be at least an order ofmagnitude higher than the LD5 of murine TNF in rodents (4, 28). The effects of rHuTNF-a on rodent GI tracts apparently persist long after the cytokine has been cleared from the blood.
Three groups have shown that TNF is rapidly cleared from the blood (t1/2 < 20 min) (32) (33) (34) and GI tract all concentrate injected '251I-TNF-a relative to plasma (33) . The GI tract has been shown to accumulate -9% of the total injected TNF after 8 min in mice (32) . However, once bound to tissue, TNF is rapidly degraded (32) , thus, the (30) . In this study there was a dramatic drop in food intake at the beginning of TNF treatment; however, the effect was transitory and food intake rebounded within 48 h. Weight loss, which occurred only in the high dose group, was also transitory and coincided with the drop in food intake and GI hemorrhage that followed the first intravenous injection. Rebound from the weight loss began by day 3, which was 7 d before neutralizing antibodies could be detected. Although Cerami and co-workers demonstrated wasting in mice injected twice daily, intraperitoneally with activated macrophage medium (20) , their study is not directly comparable to this one. Their medium may have contained a variety of agents besides TNF including endotoxin and interleukin 1 (19) ; their delivery schedule (twice per day) differed from that used in the present study (once per day); and their route of administration was different (intraperitoneal versus intravenous or intramuscular). Since tolerance did not develop to the inhibitory effect of rHuTNF-a on gastric emptying it is conceivable that weight loss from gastric blockage could occur with more frequent doses of TNF, particularly intraperitoneal doses that may deliver elevated and sustained cytokine levels to the GI tract. In this study rHuTNF-a induced retention of stomach contents was detectable for -6-7 h after an intravenous dose. Intramuscular injections caused a milder response. Clearly the animals were able to compensate for this disruption of gastric function and to grow. Perhaps during infection pulsatile production of TNF occurs with a high enough frequency that feeding is chronically suppressed and wasting occurs, or alternatively, high sustained levels produce the same effect. Further studies are underway to determine if TNF-induced gastric blockage is an important mechanism in cachexia. To date, there is no evidence that pure TNF causes wasting.
Quick adaptation to rHuTNF-a occurred in the rats such that the severe GI toxicity of the initial injection did not reappear with subsequent doses unless they were intermittent (every 5 or 10 d). Much of the inflammatory change in the intestine seen after 10 d of chronic dosing was probably associated with a normal healing response that followed the acute injury induced by the initial injection. However, chronic irritation associated with secondary microbial infections or other persistent chemotactic stimuli should also be considered as possible complicating factors. The relative increase in fecal weights in some of the rHuTNF-a-treated animals following the initial dosing probably reflect the period in which healing of the large bowel was occurring and digestion and absorption of cecal material was less efficient. Increased fecal weight could also be due to absorption by the feces of fluid lost to the intestinal lumen associated with inflammation and edema.
The rapid development of tolerance (tachyphylaxis) to the hemorrhagic effects of rHuTNF-a on the GI tract is similar to the tolerance seen in humans to some of the adverse side-effects of alpha interferon. Sherwin et al. (15) reported tachyphylaxis with fever, flulike symptoms, and GI effects, whereas fatigue and anorexia tended to be cumulative. Lau et al. have shown in vivo and in vitro that alpha interferon receptor numbers on human blood lymphocytes decreased nearly 10-fold after interferon treatment and required roughly 72 h to recover (36) . During the recovery period the cells also exhibited hyporesponsiveness to interferon treatment (36) . Thus, down regulation of TNF receptors is a possible cause ofthe tolerance seen in this study.
In summary, these results suggest that rodents are primed to respond acutely to TNF with an inflammatory response. It remains to be seen how dramatic this effect is in all tissues (37); however, the response can lead to vascular compromise, edema, hemorrhage, and with some implantable tumors this may result in a cure. Since the response requires a recovery period before it can recur it might be appropriate to use interval rather than continuous dosing for tumor therapy.
